rss
Heart 2000;83:e5 doi:10.1136/heart.83.4.e5
  • Electronic pages: case report

Acute severe thrombocytopenia after treatment with ReoPro (abciximab)

  1. R Butler,
  2. P J B Hubner
  1. Departmentt of Cardiology, Glenfield Hospital, Groby Road, Leicester LE3 9QP, UK
  1. Dr Butler email: r.butler{at}btinternet.com
  • Accepted 1 November 1999

Abstract

ReoPro (abciximab) is an extremely potent inhibitor of the glycoprotein IIb/IIIa receptor, the final common pathway of platelet activation and aggregation. Its main role is the maintenance of coronary patency after suboptimal results with coronary intervention. However, one of the complications of this treatment is excessive bleeding, a problem which may be compounded by a rare idiosyncratic thrombocytopenic reaction. A severe episode of thrombocytopenia in a 64 year old man is described; he was treated with ReoPro for a right coronary stenosis which had not been resolved by angioplasty. His platelet level dropped quickly and only improved after 20 units of platelets were given.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Latest from Education in Heart

    Latest from Education in Heart

    Register for free content


    Free trial
    Individuals may register for a free 60 day online trial to all content.

    Free archive
    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.